NOA - ELC NOTICE OF AWARD 1 NU51CK000383-01-00.PDF

4% DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 1 NUS1CK000383-01-00
FAIN# NU51CK000383
Federal Award Date: 07/10/2024

Recipient Information

Federal Award Information

1, Recipient Name
MARICOPA, COUNTY OF
4041 N Central Ave STE 1400
Phoenix, AZ 85012-3314

2. Congressional District of Recipient
03

3. Payment System Identifier (ID)
1866000472B9

4, Employer Identification Number (EIN)
866000472

5, Data Universal Numbering System (DUNS)
602062515

6. Recipient's Unique Entity Identifier (UEI)

LM85MGI513K5
7. Project Director or Principal Investigator

Dr. Jessica White
Jessica. White@Maricopa.gov
602-329-0254

8. Authorized Official

Mr. Arthur Orville
arthur.orville@maricopa.gov
6023724163

11. Award Number
1 NU51CK000383-01-00

12. Unique Federal Award Identification Number (FAIN)
NUS1ICK000383

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14, Federal Award Project Title
Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

15, Assistance Listing Number
93.323
16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type
New

18. Is the Award R&D?
No

Federal Agency Information
CDC Office of Financial Resources

9. Awarding Agency Contact Information
Ryan Smythe
Grants Management Specialist
lyt6@cde.gov
(770) 488-3629

10,Program Official Contact Information
Mrs. Janice Downing

Public Health Analyst

jsb3@cde.gov

404-639-7808

Summary Federal Award Financial Information

19, Budget Period Start Date 08/01/2024 - End Date 07/31/2025

20. Total Amount of Federal Funds Obligated by this Action $2,258,875.00
20a. Direct Cost Amount $2,053,903.00
20b. Indirect Cost Amount $204,972.00

21. Authorized Carryover $0.00

22. Offset $0.00

23. Total Amount of Federal Funds Obligated this budget period $0.00

24, Total Approved Cost Sharing or Matching, where applicable $0.00

25. Total Federal and Non-Federal Approved this Budget Period $2,258,875.00

26. Period of Performance Start Date 03/01/2024 - End Date 07/31/2029

27. Total Amount of the Federal Award including Approved
Cost Sharing or Matching this Period of Performance $2,258,875.00

28. Authorized Treatment of Program Income
ADDITIONAL COSTS

29. Grants Management Officer - Signature
Karen Zion

Grants Management Officer

30. Remarks

Page |

on

or Miata
eS
SS Nay,

Po
e

Direct Assistance

& Centers for Disease Control and Prevention

“yy DEPARTMENT OF HEALTH AND HUMAN SERVICES. Notice of Award

Award# 1 NUS1CK000383-01-00
FAIN# NUS1CK000383
Federal Award Date: 07/10/2024

BUDGET CATEGORIES PREVIOUS AMOUNT (A) AMOUNT THIS ACTION (B) TOTAL (A +B)
Personnel $0.00 $0.00 $0.00
Fringe Benefits $0.00 $0.00 $0.00
Travel $0.00 $0.00 $0.00
Equipment $0.00 $0.00 $0.00
Supplies $0.00 $0.00 $0.00
Contractual $0.00 $0.00 $0.00
Construction $0.00 $0.00 $0.00
‘Other $0.00 $0.00 $0.00
Total $0.00 $0.00 $0.00

Page 3

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and
Conditions for Non-research awards at https://www.cdc.gov/grants/federal-requlations-
policies/index,html, the Centers for Disease Control and Prevention (CDC) hereby incorporates
Notice of Funding Opportunity (NOFO) number CDC-RFA-CK-24-0002, entitied Epidemiology and
Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC), as
may be amended, which are hereby made a part of this Non-research award, hereinafter referred to
as the Notice of Award (NoA).

Total Approved Funding is included in Summary Federal Award Financial Information on page
1 of the NOA,. All future year funding will be based on satisfactory programmatic progress and the
availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the
value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount
information.

Approved Component/Project Funding: The NOFO provides for the funding of multiple components
under this award, For this NOA, the approved funding level for each component is shown below:

NOFO Component Amount Document Number
Core $ 2,145,297 24NU51CK000383
Enhanced Surveillance for $ 102,284 24NU51CKO000383JCVDC5

Vaccine-Preventable Disease

(VPD) and Respiratory Diseases
National Wastewater $ 11,294 24NU51CKO00383NWSSC6
Surveillance System

Approved but Unfunded Component/Project for this Budget Period:

Unless specifically noted (e.g., out of scope) any/all Budget Line Item (BLI) that is not funded should
be considered ‘approved but unfunded’, Should additional funds become available in the budget
period, the Program/Project may issue a revised Notice of Award (NOA) to fund these BLIs.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement
awarded by the Department of Health and Human Services (HHS) with funds made available under the
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the
Coronavirus Aid, Relief, and Economic Security Act, 2020 (the “CARES Act”) (P.L. 116-136); the
Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated
Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L.
116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to:
1) comply with existing and/or future directives and guidance from the Secretary regarding control of the
spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the
condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or
appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United
States Government in the implementation and enforcement of federal orders related to quarantine and
isolation.

stewardship of federal funds.

¢ CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and
recipients agree to the responsibilities as detailed in the NOFO and included below.

Expanded Authority: The recipient is permitted the following expanded authority in the
administration of the award.

« Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated
funds may be used for purposes within the scope of the project as originally approved. Recipients will
report use, or intended use, of carried over unobligated funds in Section 12 “Remarks” of the annual
Federal Financial Report. If the GMO determines that some or all the unobligated funds are not
necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry
over unobligated balances in the future, use the balance to reduce or offset CDC funding for a
subsequent budget period, or use a combination of these actions.

Post Award Actions Note: Post award actions may be submitted during Budget Period 1 to address
changes in work plan activities and the related costs in the approved budget. Per OGS policy, a post
award action suspense goes into effect 120 days before (i.e., April 2) the end of the budget period
(.e., July 31). This suspense is intended to protect resources necessary to conduct technical reviews
of continuation funding applications and the associated award processing activities. Therefore, any/all
financial post award actions submitted on or after April 2, 2025, will be returned. Non-financial post
award actions (e.g., change of key personnel) are not impacted by this suspense.

Budget Period 02 Continuation Guidance Note: In February 2025, the ELC Program will publish
continuation funding guidance for Budget Period 2 (BP2). In the application process for BP2,
recipients will be required to submit an interim Federal Financial Report (FFR) in ELC CAMP. As part
of this submission, recipients will be required to report the expenditures and unliquidated obligations
(ULOs) by Program/Project that were funded in BP1. Failure to submit the required information by the
due dates may result in either not being eligible or having reduced financial assistance awarded in the
Program/Project for Budget Period 2.

| FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

Recipients may not use funds for research.
Recipients may not use funds for clinical care except as allowed by law.
Recipients may use funds only for reasonable program purposes, including personnel, travel,
supplies, and services.

¢ Generally, recipients may not use funds to purchase furniture. Any such proposed spending
must have been clearly identified in the budget and be an approved BLI.

« Reimbursement of pre-award costs generally is not allowed unless the CDC provides written
approval to the recipient.

« Other than for normal and recognized executive-legislative relationships, no funds may be